Efficacy of sustained delivery of GC-1 from a Nanofluidic system in a spontaneously obese non-human primate: a case study

Research output: Contribution to journalArticle

Carly S. Filgueira, Giacomo Bruno, Zachary W. Smith, Corrine Ying Xuan Chua, Andrea Ballerini, Marco Folci, April L. Gilbert, Priya Jain, Jagannadha K. Sastry, Pramod N. Nehete, Kathryn A. Shelton, Lori R. Hill, Areeba Ali, Keith A. Youker, Alessandro Grattoni

With nearly 40% of U.S. adults obese, and childhood and adolescent rates rising, obesity and associated comorbidities are serious public health concerns with massive societal costs. Often, lifestyle interventions do not offer sufficient weight loss to improve health, requiring surgery and medications as adjunct management strategies. Here, we present a 4-month case study in which the sustained, low-dose, and constant administration of the thyroid receptor β selective agonist GC-1 (sobetirome) from a novel nanochannel membrane implant was assessed in an obese, pre-diabetic rhesus macaque. Dramatic loss of white adipose tissue in the abdomen from 36 to 18% was observed via magnetic resonance imaging in conjunction with normalized serum insulin and glycemia, with no signs of cardiotoxicity shown. The non-human primate study highlights sustained low-dose delivery of GC-1 from our minimally invasive subcutaneous implant as a valuable approach to induce weight loss and manage obesity and comorbidities, including type 2 diabetes.

Original languageEnglish (US)
Article number49
JournalBiomedical Microdevices
Volume20
Issue number2
DOIs
StatePublished - Jun 1 2018

PMID: 29916059

Altmetrics

Cite this

Standard

Efficacy of sustained delivery of GC-1 from a Nanofluidic system in a spontaneously obese non-human primate : a case study. / Filgueira, Carly S.; Bruno, Giacomo; Smith, Zachary W.; Chua, Corrine Ying Xuan; Ballerini, Andrea; Folci, Marco; Gilbert, April L.; Jain, Priya; Sastry, Jagannadha K.; Nehete, Pramod N.; Shelton, Kathryn A.; Hill, Lori R.; Ali, Areeba; Youker, Keith A.; Grattoni, Alessandro.

In: Biomedical Microdevices, Vol. 20, No. 2, 49, 01.06.2018.

Research output: Contribution to journalArticle

Harvard

Filgueira, CS, Bruno, G, Smith, ZW, Chua, CYX, Ballerini, A, Folci, M, Gilbert, AL, Jain, P, Sastry, JK, Nehete, PN, Shelton, KA, Hill, LR, Ali, A, Youker, KA & Grattoni, A 2018, 'Efficacy of sustained delivery of GC-1 from a Nanofluidic system in a spontaneously obese non-human primate: a case study' Biomedical Microdevices, vol. 20, no. 2, 49. DOI: 10.1007/s10544-018-0296-2

APA

Filgueira, C. S., Bruno, G., Smith, Z. W., Chua, C. Y. X., Ballerini, A., Folci, M., ... Grattoni, A. (2018). Efficacy of sustained delivery of GC-1 from a Nanofluidic system in a spontaneously obese non-human primate: a case study. Biomedical Microdevices, 20(2), [49]. DOI: 10.1007/s10544-018-0296-2

Vancouver

Filgueira CS, Bruno G, Smith ZW, Chua CYX, Ballerini A, Folci M et al. Efficacy of sustained delivery of GC-1 from a Nanofluidic system in a spontaneously obese non-human primate: a case study. Biomedical Microdevices. 2018 Jun 1;20(2). 49. Available from, DOI: 10.1007/s10544-018-0296-2

Author

Filgueira, Carly S. ; Bruno, Giacomo ; Smith, Zachary W. ; Chua, Corrine Ying Xuan ; Ballerini, Andrea ; Folci, Marco ; Gilbert, April L. ; Jain, Priya ; Sastry, Jagannadha K. ; Nehete, Pramod N. ; Shelton, Kathryn A. ; Hill, Lori R. ; Ali, Areeba ; Youker, Keith A. ; Grattoni, Alessandro. / Efficacy of sustained delivery of GC-1 from a Nanofluidic system in a spontaneously obese non-human primate : a case study. In: Biomedical Microdevices. 2018 ; Vol. 20, No. 2.

BibTeX

@article{b29f0157c8114604a1077316a05bdf1d,
title = "Efficacy of sustained delivery of GC-1 from a Nanofluidic system in a spontaneously obese non-human primate: a case study",
abstract = "With nearly 40{\%} of U.S. adults obese, and childhood and adolescent rates rising, obesity and associated comorbidities are serious public health concerns with massive societal costs. Often, lifestyle interventions do not offer sufficient weight loss to improve health, requiring surgery and medications as adjunct management strategies. Here, we present a 4-month case study in which the sustained, low-dose, and constant administration of the thyroid receptor β selective agonist GC-1 (sobetirome) from a novel nanochannel membrane implant was assessed in an obese, pre-diabetic rhesus macaque. Dramatic loss of white adipose tissue in the abdomen from 36 to 18{\%} was observed via magnetic resonance imaging in conjunction with normalized serum insulin and glycemia, with no signs of cardiotoxicity shown. The non-human primate study highlights sustained low-dose delivery of GC-1 from our minimally invasive subcutaneous implant as a valuable approach to induce weight loss and manage obesity and comorbidities, including type 2 diabetes.",
keywords = "GC-1, Non-human primate, Sobetirome, Sustained release, Thyroid hormone mimetics",
author = "Filgueira, {Carly S.} and Giacomo Bruno and Smith, {Zachary W.} and Chua, {Corrine Ying Xuan} and Andrea Ballerini and Marco Folci and Gilbert, {April L.} and Priya Jain and Sastry, {Jagannadha K.} and Nehete, {Pramod N.} and Shelton, {Kathryn A.} and Hill, {Lori R.} and Areeba Ali and Youker, {Keith A.} and Alessandro Grattoni",
year = "2018",
month = "6",
day = "1",
doi = "10.1007/s10544-018-0296-2",
language = "English (US)",
volume = "20",
journal = "Biomedical Microdevices",
issn = "1387-2176",
publisher = "Kluwer Academic Publishers",
number = "2",

}

RIS

TY - JOUR

T1 - Efficacy of sustained delivery of GC-1 from a Nanofluidic system in a spontaneously obese non-human primate

T2 - Biomedical Microdevices

AU - Filgueira,Carly S.

AU - Bruno,Giacomo

AU - Smith,Zachary W.

AU - Chua,Corrine Ying Xuan

AU - Ballerini,Andrea

AU - Folci,Marco

AU - Gilbert,April L.

AU - Jain,Priya

AU - Sastry,Jagannadha K.

AU - Nehete,Pramod N.

AU - Shelton,Kathryn A.

AU - Hill,Lori R.

AU - Ali,Areeba

AU - Youker,Keith A.

AU - Grattoni,Alessandro

PY - 2018/6/1

Y1 - 2018/6/1

N2 - With nearly 40% of U.S. adults obese, and childhood and adolescent rates rising, obesity and associated comorbidities are serious public health concerns with massive societal costs. Often, lifestyle interventions do not offer sufficient weight loss to improve health, requiring surgery and medications as adjunct management strategies. Here, we present a 4-month case study in which the sustained, low-dose, and constant administration of the thyroid receptor β selective agonist GC-1 (sobetirome) from a novel nanochannel membrane implant was assessed in an obese, pre-diabetic rhesus macaque. Dramatic loss of white adipose tissue in the abdomen from 36 to 18% was observed via magnetic resonance imaging in conjunction with normalized serum insulin and glycemia, with no signs of cardiotoxicity shown. The non-human primate study highlights sustained low-dose delivery of GC-1 from our minimally invasive subcutaneous implant as a valuable approach to induce weight loss and manage obesity and comorbidities, including type 2 diabetes.

AB - With nearly 40% of U.S. adults obese, and childhood and adolescent rates rising, obesity and associated comorbidities are serious public health concerns with massive societal costs. Often, lifestyle interventions do not offer sufficient weight loss to improve health, requiring surgery and medications as adjunct management strategies. Here, we present a 4-month case study in which the sustained, low-dose, and constant administration of the thyroid receptor β selective agonist GC-1 (sobetirome) from a novel nanochannel membrane implant was assessed in an obese, pre-diabetic rhesus macaque. Dramatic loss of white adipose tissue in the abdomen from 36 to 18% was observed via magnetic resonance imaging in conjunction with normalized serum insulin and glycemia, with no signs of cardiotoxicity shown. The non-human primate study highlights sustained low-dose delivery of GC-1 from our minimally invasive subcutaneous implant as a valuable approach to induce weight loss and manage obesity and comorbidities, including type 2 diabetes.

KW - GC-1

KW - Non-human primate

KW - Sobetirome

KW - Sustained release

KW - Thyroid hormone mimetics

UR - http://www.scopus.com/inward/record.url?scp=85048726214&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048726214&partnerID=8YFLogxK

U2 - 10.1007/s10544-018-0296-2

DO - 10.1007/s10544-018-0296-2

M3 - Article

VL - 20

JO - Biomedical Microdevices

JF - Biomedical Microdevices

SN - 1387-2176

IS - 2

M1 - 49

ER -

ID: 39882350